Neumora Therapeutics Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neumora Therapeutics advances neuroscience pipeline with promising MDD treatment

Neumora Therapeutics is strategically positioned with a focus on brain disease treatments, a diversified pipeline, and a strong cash position supporting operations.
While facing challenges in managing expenses and meeting market expectations, the company's proactive approach and promising pipeline offer opportunities for growth and innovation.
Investors should monitor Neumora's progress on upcoming clinical catalysts and the successful development of Navacaprant for various indications to gauge future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed significant efficacy in a phase 2 study for MDD and is also being tested for bipolar depression, with phase 2 data expected in late 2025. Neumora has $341.3 million in cash, enough to fund operations until mid-2026, minimizing near-term dilution risk unless management opts otherwise.

Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.

This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch – President and Chief Executive Officer Josh Pinto – Chief Financial Officer Rob Lenz – Head of Research and Development Conference Call Participants Julian Pino – Stifel Brian Abrahams – RBC Capital Markets Myles Minter – William Blair Charles Wang – Mizuho Douglas Tsao – H.C. Wainwright Charlie Yang – Bank of America Operator Ladies and gentlemen, thank you for standing by.

Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November:

Neumora Therapeutics to Participate in Upcoming Conferences in November

Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET

Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation

Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

Neumora Therapeutics (NASDAQ: NMRA ) just reported results for the first quarter of 2024. Neumora Therapeutics reported earnings per share of -34 cents.

NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024

On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

Neumora said Monday the FDA put its schizophrenia drug on hold after rabbits experienced convulsions, and the biotech stock plunged.

Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug

Neumora Therapeutics (NASDAQ: NMRA ) stock is falling on Monday after the clinical-stage biopharmaceutical company announced a clinical hold on a Phase 1 trial of NMRA-266. The Food and Drug Administration (FDA) is behind this clinical hold on NMRA-266.

Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?

Neumora Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) had placed a clinical hold on early-stage study of its experimental schizophrenia drug, sending its shares down more than 23% in premarket trading.

Neumora's early-stage schizophrenia drug study put on hold

WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive allosteric modulator (PAM) of the M4 muscarinic receptor and is part of the Company's M4 PAM franchise. The clinical hold determination follows recently available pre-clinical data showing convulsions in rabbits.

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 11:00 a.m. ET.

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora's executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia.

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

Neumora Therapeutics (NMRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Monday, January 8, 2024 at 11:15 a.m. PT (2:15 p.m. ET).

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Bristol-Myers

Darling Ingredients

Funko

Occidental Petroleum

STAAR Surgical

Westrock Coffee Holdings LLC

Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is undervalued.

7 Stocks with Strong Insider Buying: December 2023

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer. Mr. Duncan will be a member of Neumora's Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company's legal and compliance functions.

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

Birkenstock Holding Plc

Instacart (Maplebear Inc.)

Klaviyo, Inc. 

Smith Douglas Homes Corp

VinFast Auto Ltd

Waystar Holding Corp

ZEEKR Intelligent Technology Holding Ltd

The U.S. initial public offering calendar is empty this holiday-shortened week, but some recent additions to the pipeline suggest December could be livelier and welcome deals from some profitable, decent-sized companies.

News for Neumora Therapeutics Inc Stock (NMRA)